Bong-sook Baek

Array ( [id] => 19550909 [patent_doc_number] => 12134605 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-05 [patent_title] => Substituted 1,2,4-triazoles and methods of use [patent_app_type] => utility [patent_app_number] => 17/127797 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 36 [patent_no_of_words] => 29494 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20187048 [patent_doc_number] => 12398153 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-26 [patent_title] => Spiro compound serving as ERK inhibitor, and application thereof [patent_app_type] => utility [patent_app_number] => 17/782850 [patent_app_country] => US [patent_app_date] => 2020-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 8134 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091292 [patent_doc_number] => 20220409633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => COMPOSITION COMPRISING BUDESONIDE FOR OPHTHALMIC USE [patent_app_type] => utility [patent_app_number] => 17/777964 [patent_app_country] => US [patent_app_date] => 2020-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17777964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18150078 [patent_doc_number] => 20230023935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => USE OF MASITINIB FOR THE TREATMENT OF EOSINOPHILIC ASTHMA [patent_app_type] => utility [patent_app_number] => 17/779722 [patent_app_country] => US [patent_app_date] => 2020-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18107988 [patent_doc_number] => 20230000868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => USE OF 2-PHENYL-6-(1H-IMIDAZOL-1-YL) QUINAZOLINE FOR THE PREVENTION OF ABUSE AND OF SIDE EFFECTS OF AT LEAST ONE OPIOID [patent_app_type] => utility [patent_app_number] => 17/780608 [patent_app_country] => US [patent_app_date] => 2020-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18107988 [patent_doc_number] => 20230000868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => USE OF 2-PHENYL-6-(1H-IMIDAZOL-1-YL) QUINAZOLINE FOR THE PREVENTION OF ABUSE AND OF SIDE EFFECTS OF AT LEAST ONE OPIOID [patent_app_type] => utility [patent_app_number] => 17/780608 [patent_app_country] => US [patent_app_date] => 2020-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18125342 [patent_doc_number] => 20230010958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => CANNABINOID AND LYCOPENE ANTI-INFLAMMATORY SYNERGISTIC COMBINATIONS [patent_app_type] => utility [patent_app_number] => 17/780149 [patent_app_country] => US [patent_app_date] => 2020-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9454 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710281 [patent_doc_number] => 20210077428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/100456 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17100456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091260 [patent_doc_number] => 20220409601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => COMBINATION CANNABINOID-NAD+ PRECURSOR FORMULATION FOR TREATMENT OF INFLAMMATION AND METHODS RELATED THERETO [patent_app_type] => utility [patent_app_number] => 17/778821 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5206 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17250047 [patent_doc_number] => 11185515 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => Bupropion as a modulator of drug activity [patent_app_type] => utility [patent_app_number] => 16/952759 [patent_app_country] => US [patent_app_date] => 2020-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 24 [patent_no_of_words] => 63662 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16952759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710336 [patent_doc_number] => 20210077483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/950838 [patent_app_country] => US [patent_app_date] => 2020-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710336 [patent_doc_number] => 20210077483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/950838 [patent_app_country] => US [patent_app_date] => 2020-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710336 [patent_doc_number] => 20210077483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/950838 [patent_app_country] => US [patent_app_date] => 2020-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710336 [patent_doc_number] => 20210077483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/950838 [patent_app_country] => US [patent_app_date] => 2020-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710336 [patent_doc_number] => 20210077483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/950838 [patent_app_country] => US [patent_app_date] => 2020-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710336 [patent_doc_number] => 20210077483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/950838 [patent_app_country] => US [patent_app_date] => 2020-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710336 [patent_doc_number] => 20210077483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/950838 [patent_app_country] => US [patent_app_date] => 2020-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710336 [patent_doc_number] => 20210077483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/950838 [patent_app_country] => US [patent_app_date] => 2020-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671242 [patent_doc_number] => 20210060005 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/097486 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63845 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17097486 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441770 [patent_doc_number] => 20220062275 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-03-03 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/095256 [patent_app_country] => US [patent_app_date] => 2020-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63540 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 171 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17095256 [rel_patent_id] =>[rel_patent_doc_number] =>)